Latest

Opposites Attract: Pairing R&D and Commercial Teams

Meike Wenzel and Clifford Hall examine a new concept for early commercialization planning to facilitate good cross-functional working practice.

Biosimilars: The Litigation and Patent Challenges to Come

Intellectual property lawyers estimate biosimilar litigation will swell as early as 2018.

New & Noteworthy

What’s Real in Rare Disease: A Pharm Exec Roundtable

Pharm Exec convened an expert panel on rare disease to highlight the challenges of serving expectant patients in this uniquely complex market access environment.

Women in the Pharma Workplace: A View from Europe

William Looney speaks to Dr. Claudia Graeve, who leads the Healthcare Businesswomen's Association in Europe, on improving the prospects for female managers.

South African Start-Ups: Bridging the "Valley of Death"

South Africa may have the most developed market for biopharmaceuticals on the African continent, but there are a few critical shortcomings, writes William Looney.

Finding and Funding the Cure for Alzheimer's Disease

Biogen’s aducanumab offers renewed hope for an Alzheimer's Disease solution, but funding challenges remain, writes Ed Schoonveld.

From the Editor

South African Start-Ups: Bridging the "Valley of Death"

South Africa may have the most developed market for biopharmaceuticals on the African continent, but there are a few critical shortcomings, writes William Looney.

The New Health: Navigating with Nash

Learnings gleaned from our annual EAB meeting, hosted this year by Dr. David Nash, Dean of the Thomas Jefferson University School of Population Health.

Is There Gold in the DNA Selfie?

Pharma jumps on board personal genomics train—at least for test drive—but will journey ultimately help transform treatment or stall out as just another fad?

Europe

Edging Through Europe's HTA Jungle

Reflector edges through the complex terrain that is health technology assessment in Europe.

Sunshine Over Europe: Event Sheds Light on Disclosure

Sunshine was a strong feature of this week's CBI’s Global Transparency Reporting Congress in London, in more ways than one.

Evaluating the Impact of the Falsified Medicines Directive in Switzerland

As the prevalence of falsified medicines increases, Switzerland is taking measures to secure its supply chain.

Global

Sunshine Over Europe: Event Sheds Light on Disclosure

Sunshine was a strong feature of this week's CBI’s Global Transparency Reporting Congress in London, in more ways than one.

The Goods and Services Tax: A Bane or a Boon for Indian Pharma?

Dr. Anuj Gupta explains the potential implications of the GST— or the goods and services tax — on Indian pharma.

Europe: Researching New Drugs "Needs Research into New Pricing Systems"

In Europe drug pricing concerns are continuing to invade the hitherto sacrosanct territory of drug development, writes Peter O'Donnell.

PEspeaks

“Take a Breath” on the Specialty Drug Pricing Issue…?

Watching the latest volleys fly in the ongoing specialty drug pricing wars, Tom Norton wonders: Is it possible that all involved couldn’t just step back and take a breath?

#WMIF15’s Disruptive Dozen

Neuroscience luminaries clamored onto the stage at this week's World Medical Innovation Forum in Boston to present the meeting’s much-anticipated "Disruptive Dozen".

Pharma Gains Marketing Flexibility, Loses Exclusivities in Revised “Cures” Proposal

The revised Cures proposal makes it easier for pharma to distribute journal articles and medical textbooks to physicians, but it also drops provisions that provided added exclusivity for certain new therapies.

Biogen CEO Highlights Neuroscience Innovation Forum

Pricing and Sovaldi couldn’t avoid mention at this week’s World Medical Innovation Forum put on by Partners Healthcare in Boston. The meeting highlighted multiple issues in neuroscience but also touched on hot buttons across the industry.

Regulatory

Pharma Gains Marketing Flexibility, Loses Exclusivities in Revised “Cures” Proposal

The revised Cures proposal makes it easier for pharma to distribute journal articles and medical textbooks to physicians, but it also drops provisions that provided added exclusivity for certain new therapies.

Medical Apps Tricky for Pharma

The industry continues to puzzle over FDA's proposed regulation of mobile medical apps (MMAs), writes Jill Wechsler.

The Power of Proactive Pharmacovigilance

The need for proactive pharmacovigilance is being increasingly acknowledged by all companies, regardless of their size and product mix, writes Dr. Chitra Lele.

Sales & Marketing

Data is Now the Key to Marketing

Neil Gleghorn, looks at the upsurge of technology and metric-driven marketing operations in the strictly regulated pharmaceutical industries.

Are Times A-Changing for Drug Marketing?

FDA is under pressure to moderate oversight of pharma advertising and promotion, writes Jill Wechsler.

So What is Pharma’s Ideal Role in Social?

Advertorial: Ashfield Commercial & Medical Services believes that Pharma can use social media to play an important role in educating the healthcare professional (HCP) and the patient

R&D

Refuting R&D Tax Credit Myths

Why executives should make the US R&D tax credit part of their planning discussions, by Chai Hoang and Chris Bard.

Pharmacies — A New Patient Education Opportunity

Kenneth Getz of the Tufts Center for the Study of Drug Development looks at leveraging pharmacists as a channel to raise clinical research literacy among patient communities.

Strategy

Is Procurement Living Up to the Challenge?

Mike Straw offers four key changes to address the "lack of love" for pharmaceutical procurement functions.

Should You Outsource Analytics?

Successful outsourcing can provide pharma companies with high-value, cost-effective analytics. But there are challenges, write Ram Moorthy and Dharmendra Sahay.

The Power of Proactive Pharmacovigilance

The need for proactive pharmacovigilance is being increasingly acknowledged by all companies, regardless of their size and product mix, writes Dr. Chitra Lele.